Model-inferred mechanisms of liver function from magnetic resonance imaging data: Validation and variation across a clinically relevant cohort

Estimation of liver function is important to monitor progression of chronic liver disease (CLD). A promising method is magnetic resonance imaging (MRI) combined with gadoxetate, a liver-specific contrast agent. For this method, we have previously developed a model for an average healthy human. Herein, we extended this model, by combining it with a patient-specific non-linear mixed-effects modeling framework. We validated the model by recruiting 100 patients with CLD of varying severity and etiologies. The model explained all MRI data and adequately predicted both timepoints saved for validation and gadoxetate concentrations in both plasma and biopsies. The validated model provides a new and deeper look into how the mechanisms of liver function vary across a wide variety of liver diseases. The basic mechanisms remain the same, but increasing fibrosis reduces uptake and increases excretion of gadoxetate. These mechanisms are shared across many liver functions and can now be estimated from standard clinical images.

[1]  Gunnar Cedersund,et al.  Nonlinear mixed-effects modelling for single cell estimation: when, why, and how to use it , 2015, BMC Systems Biology.

[2]  Li Wang,et al.  Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative Proteomics , 2016, Drug Metabolism and Disposition.

[3]  J. Senior,et al.  Alanine Aminotransferase: A Clinical and Regulatory Tool for Detecting Liver Injury–Past, Present, and Future , 2012, Clinical pharmacology and therapeutics.

[4]  Marcus J. Tindall,et al.  Multi-scale, whole-system models of liver metabolic adaptation to fat and sugar in non-alcoholic fatty liver disease , 2018, npj Systems Biology and Applications.

[5]  É. Moulines,et al.  Convergence of a stochastic approximation version of the EM algorithm , 1999 .

[6]  J. Senior,et al.  Drug-related hepatotoxicity. , 2006, The New England journal of medicine.

[7]  Joanna W Etra,et al.  Early identification of patients at increased risk for hepatic insufficiency, complications and mortality after major hepatectomy. , 2014, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[8]  Huiru Zheng,et al.  Evaluating a common semi-mechanistic mathematical model of gene-regulatory networks , 2015, BMC Systems Biology.

[9]  Paolo Borro,et al.  13C-galactose breath test and 13C-aminopyrine breath test for the study of liver function in chronic liver disease. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  Gerd A. Kullak-Ublick,et al.  Expression of the hepatocyte canalicular multidrug resistance protein (MRP2) in primary biliary cirrhosis. , 2002, Hepatology research : the official journal of the Japan Society of Hepatology.

[11]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[12]  P. Boesiger,et al.  SENSE: Sensitivity encoding for fast MRI , 1999, Magnetic resonance in medicine.

[13]  P. Sandström,et al.  Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study , 2012, European Radiology.

[14]  W. T. Dixon Simple proton spectroscopic imaging. , 1984, Radiology.

[15]  Hiroshi Honda,et al.  Quantitative analysis of liver function using superparamagnetic iron oxide- and Gd-EOB-DTPA-enhanced MRI: comparison with Technetium-99m galactosyl serum albumin scintigraphy. , 2012, European journal of radiology.

[16]  Markus Grube,et al.  Hepatic Uptake of the Magnetic Resonance Imaging Contrast Agent Gd-EOB-DTPA: Role of Human Organic Anion Transporters , 2010, Drug Metabolism and Disposition.

[17]  H. Hussain,et al.  Primovist, Eovist: what to expect? , 2012, Journal of hepatology.

[18]  J. Boyer,et al.  Bile salt transporters: molecular characterization, function, and regulation. , 2003, Physiological reviews.

[19]  J. Naish,et al.  Quantitative Assessment of Liver Function Using Gadoxetate-Enhanced Magnetic Resonance Imaging , 2016, Investigative radiology.

[20]  Helmut Ringl,et al.  Post-hepatectomy liver failure after major hepatic surgery: not only size matters , 2018, European Radiology.

[21]  S. Bulik,et al.  HEPATOKIN1 is a biochemistry-based model of liver metabolism for applications in medicine and pharmacology , 2018, Nature Communications.

[22]  Gunnar Cedersund,et al.  Insulin Signaling in Type 2 Diabetes , 2013, The Journal of Biological Chemistry.

[23]  Neil Woodhouse,et al.  Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibition , 2013, NMR in biomedicine.

[24]  Sheung Tat Fan,et al.  Liver functional reserve estimation: state of the art and relevance for local treatments , 2010, Journal of hepato-biliary-pancreatic sciences.

[25]  U. Motosugi,et al.  Liver parenchymal enhancement of hepatocyte‐phase images in Gd‐EOB‐DTPA‐enhanced MR imaging: Which biological markers of the liver function affect the enhancement? , 2009, Journal of magnetic resonance imaging : JMRI.

[26]  Osamu Matsui,et al.  Signal profile on Gd-EOB-DTPA-enhanced MR imaging in non-alcoholic steatohepatitis and liver cirrhosis induced in rats: correlation with transporter expression , 2011, European Radiology.

[27]  Lorella Pascolo,et al.  Gene Expression of ABC Proteins in Hepatocellular Carcinoma, Perineoplastic Tissue, and Liver Diseases , 2002, Molecular medicine.

[28]  Örjan Smedby,et al.  Consistent intensity inhomogeneity correction in water–fat MRI , 2015, Journal of magnetic resonance imaging : JMRI.

[29]  Kwan Soo Hong,et al.  Pre-Hepatectomy Assessment of Bile Transporter Expression by Gadoxetic Acid-Enhanced MRI in a Rat Model of Liver Cirrhosis , 2017, Journal of investigative surgery : the official journal of the Academy of Surgical Research.

[30]  P S Tofts,et al.  The relaxivity of Gd-EOB-DTPA and Gd-DTPA in liver and kidney of the Wistar rat. , 1996, Magnetic resonance imaging.

[31]  Michal Heger,et al.  The emerging role of transport systems in liver function tests. , 2012, European journal of pharmacology.

[32]  Osamu Matsui,et al.  Cirrhotic rat liver: reference to transporter activity and morphologic changes in bile canaliculi--gadoxetic acid-enhanced MR imaging. , 2010, Radiology.

[33]  K. Batts,et al.  Chronic hepatitis. An update on terminology and reporting. , 1995, The American journal of surgical pathology.

[34]  Jiri Aubrecht,et al.  Development of Blood Biomarkers for Drug-Induced Liver Injury: An Evaluation of Their Potential for Risk Assessment and Diagnostics , 2013, Molecular Diagnosis & Therapy.

[35]  Steven Sourbron,et al.  Assessing liver function using dynamic Gd‐EOB‐DTPA‐enhanced MRI with a standard 5‐phase imaging protocol , 2013, Journal of magnetic resonance imaging : JMRI.

[36]  Benjamin Leporq,et al.  Quantification of hepatic perfusion and hepatocyte function with dynamic gadoxetic acid-enhanced MRI in patients with chronic liver disease. , 2018, Clinical science.

[37]  Magnus Borga,et al.  Robust water fat separated dual‐echo MRI by phase‐sensitive reconstruction , 2017, Magnetic resonance in medicine.

[38]  Robert M. Marks,et al.  Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. , 2015, AJR. American journal of roentgenology.

[39]  A Namiki,et al.  Noninvasive ICG clearance test for estimating hepatic blood flow during halothane and isoflurane anaesthesia , 1995, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[40]  Peter Lundberg,et al.  Physiologically Realistic and Validated Mathematical Liver Model Revels Hepatobiliary Transfer Rates for Gd-EOB-DTPA Using Human DCE-MRI Data , 2014, PloS one.

[41]  Jean-Luc Daire,et al.  Advanced fibrosis: Correlation between pharmacokinetic parameters at dynamic gadoxetate-enhanced MR imaging and hepatocyte organic anion transporter expression in rat liver. , 2015, Radiology.

[42]  James S MacDonald,et al.  Toxicity testing in the 21st century: a view from the pharmaceutical industry. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[43]  F Uggeri,et al.  Abc protein transport of MRI contrast agents in canalicular rat liver plasma vesicles and yeast vacuoles. , 2001, Biochemical and biophysical research communications.

[44]  M. Reiser,et al.  Combined quantification of liver perfusion and function with dynamic gadoxetic acid-enhanced MR imaging. , 2012, Radiology.

[45]  Pascal Spincemaille,et al.  Diagnostic accuracy of intracellular uptake rates calculated using dynamic Gd‐EOB‐DTPA‐enhanced MRI for hepatic fibrosis stage , 2017, Journal of magnetic resonance imaging : JMRI.

[46]  Claude B. Sirlin,et al.  Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid , 2016, Abdominal Radiology.

[47]  Xi Yang,et al.  A multi-center preclinical study of gadoxetate DCE-MRI in rats as a biomarker of drug induced inhibition of liver transporter function , 2018, PloS one.

[48]  Frank Wacker,et al.  An Imaging Biomarker for Assessing Hepatic Function in Patients With Primary Sclerosing Cholangitis , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[49]  Natal A W van Riel,et al.  Requirements for multi-level systems pharmacology models to reach end-usage: the case of type 2 diabetes , 2016, Interface Focus.